

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement made by Consun Pharmaceutical Group Limited (the “**Company**”) on 25 July 2022 (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those in the Announcement.

According to the Announcement, it was stated that it was the intention of the Potential Vendors and the Potential Purchaser that the parties would not proceed with the Potential Disposal if it triggered a mandatory unconditional cash offer for all the issued shares in the Company under The Hong Kong Code on Takeovers and Mergers (the “**Takeovers Code**”). The Board would like to clarify that it should be the intention of the Potential Vendors and the Potential Purchaser that in the event conditional mandatory general offer obligation under Rule 26 of the Takeovers Code is triggered under the existing terms of the Potential Disposal, the parties will negotiate to revise the terms of the Proposed Disposal such that no mandatory general offer obligation under Rule 26 of the Takeovers Code will be triggered.

In addition, the Directors understand that they should have included the responsibility statement as required under Rule 9.3 of the Takeovers Codes in the Announcement. They hereby confirm that they jointly and severally accept full responsibility for the accuracy of information contained in the Announcement and the Directors confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in the Announcement have been arrived at after due and careful consideration and there are no other facts not contained in the Announcement, the omission of which would make any statement in the Announcement misleading.

Save for the clarification and supplementary information stated in this announcement, all information in the Announcement remains unchanged.

By order of the Board of
Consun Pharmaceutical Group Limited
An Meng
Chairman

Hong Kong, 26 July 2022

As at the date of this announcement, the Board comprises Mr. An Meng, Ms. Li Qian, Professor Zhu Quan and Mr. Xu Hanxing as executive Directors; Ms. Zhang Lihua as a non-executive Director; and Mr. Su Yuanfu, Mr. Feng Zhongshi and Ms. Chen Yujun as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement, and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statements in this announcement misleading.